RNAconnect released preprint data for UltraMarathonRT, a group II intron reverse transcriptase that reportedly captures more full‑length transcripts in single‑cell RNA‑seq than retroviral RTs, revealing previously missed genes and RNA features. Authors claim the enzyme’s processivity and helicase activity can expand transcriptomic coverage and enable new single‑cell assays. In a separate legal development, Parse Biosciences prevailed in a federal decision invalidating a Scale Biosciences patent asserted by 10x Genomics, a ruling that removes a prominent IP obstacle for alternative single‑cell library approaches. The juxtaposition of technical innovation and patent litigation highlights competitive pressure in single‑cell workflows and the commercial value of enabling chemistries and enzymes.